Compare Adobe Systems Inc (ADBE) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Mesoblast Limited — how do they compare? Adobe Systems Inc trades at $256.06 (market cap $104.82B), while Mesoblast Limited trades at $16.83 (market cap $2.21B). The key difference: Adobe Systems Inc is far larger — about 47.4× Mesoblast Limited's market cap, and Mesoblast Limited is trading nearer its 52-week high, Adobe Systems Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | MESO | |
|---|---|---|
Market Cap | $104.82B | $2.21B |
Volume | 5,187,646 | — |
Sector | Technology | Technology |
52-Week High | $367.46 | $20.96 |
52-Week Low | $193.41 | $12.88 |
Enterprise Value | $106.26B | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe Inc. (ADBE) is trading at $255.80, down 6.29% in the last 24 hours amid broader tech sector volatility. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $5.96 beating expectations of $5.82. Revenue growth remains robust at $23.77B in 2025, with net income margin expanding to 29.99%. Technical indicators show a bullish moving average signal but neutral oscillators, with key support at $252.
Adobe presents a compelling value opportunity with a P/E of 15.09 below historical averages, though AI competition and CEO transition risks warrant caution. Analyst consensus remains positive with 49.2% buy ratings and $248.86 price target, suggesting potential upside from current levels despite recent selloff.
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
